Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Significant Increase in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 10,331,073 shares, an increase of 144.0% from the July 30th total of 4,234,144 shares. Based on an average daily volume of 60,973,817 shares, the short-interest ratio is currently 0.2 days. Approximately 1,266.1% of the shares of the company are short sold.

Liminatus Pharma Stock Up 2.0%

Shares of LIMN opened at $4.49 on Friday. The firm has a market capitalization of $4.53 million, a PE ratio of -0.19 and a beta of 5.35. The firm has a 50-day moving average price of $5.73 and a 200 day moving average price of $9.56. Liminatus Pharma has a 52-week low of $4.26 and a 52-week high of $154.50.

Liminatus Pharma (NASDAQ:LIMN) last released its quarterly earnings results on Friday, August 14th. The company reported ($1.50) EPS for the quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings raised Liminatus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Wall Street Zen lowered Liminatus Pharma to a “strong sell” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.